azacitidine; 5-azacytidine (Vidaza, Onureg)
Jump to navigation
Jump to search
Introduction
Tradename: Vidaza (FDA-approved in 2004)
Indications
- treatment of myelodysplastic syndrome[1]
- maintenance therapy for acute myeloid leukemia in 1st remission[2]
Mechanism of action
- biomimetic, pyrimidine analog
Notes
Manufacturers: Pharmion (Vidaza), Bristol-Myers Squibb (Onureg)
More general terms
- pyrimidine antimetabolite; antimetabolite; pyrimidine analog
- antineoplastic agent (chemotherapeutic agent)
References
- ↑ 1.0 1.1 Prescriber's Letter 12(2): 2005 New Drugs Approved by the FDA in 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210216&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Bankhead C Year in Review: Acute Myeloid Leukemia. MedPage Today November 29, 2020 https://www.medpagetoday.com/hematologyoncology/leukemia/89909
- ↑ Department of Veterans Affairs, VA National Formulary